LETTER TO THE EDITOR

Teclistamab *versus* B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis

Authors

Junmin Song,[1] Cho-Han Chiang,[2] Stepan Esagian,[1] Gagi Kim,[3] Kuan-Yu Chi,[1] Yu Chang,[4] Terri Parker[5] and Ansh K. Mehta[6]

[1]Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; [2]Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA; [3]Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea; [4]Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; [5]Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA and [6]Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Correspondence:
A.K. MEHTA - AnshK_Mehta@dfci.harvard.edu
am.online.1100@gmail.com
T.PARKER - terri.parker@yale.edu

https://doi.org/10.3324/haematol.2024.287215

Received: December 18, 2024.
Accepted: April 3, 2025.
Early view: April 10, 2025.

Supplementary Table 1. Variables used in the analysis

Characteristic Name	ICD-10 or TriNetX codes
Basic demographics	
Age, mean	Built-in variable selection
Male	Built-in variable selection
Female	Built-in variable selection
White	Built-in variable selection
Black or African American	Built-in variable selection
Asian	Built-in variable selection
Hispanic or Latino	Built-in variable selection
Underlying comorbidities	
Type 2 diabetes mellitus	E11
Hypertensive diseases	I10-I1A
Heart failure	I50
Ischemic heart diseases	I20-I25
Chronic lower respiratory diseases	J40-4A
Cerebral infarction	I63
Malnutrition	E40-E46
Diseases of liver	K70-K77
Systemic connective tissue disorders	M30-M36
Bone fracture	M84
Anemia	D64.9
Immunodeficiency	D84.9
Neutropenia	D70
Joint pain	M25
Laboratory values	
Hemoglobin	9014
Serum creatinine	9024
Serum albumin	9045
Serum lactate dehydrogenase (LDH)	9052
Serum beta-2-microglobulin	LG6147-5
Body mass index (BMI)	9083
Treatment for multiple myeloma	
Autologous stem cell transplantation	38241
dexamethasone	3264
lenalidomide	342369
thalidomide	10432
bortezomib	358258

ixazomib	1723735
carfilzomib	1302966
pomalidomide	1369713
daratumumab	1721947

Supplementary Table 2. Raw survival probabilities from Kaplan-Meier curves for all-cause mortality, cytokine release syndrome, and immune effector cell-associated neurotoxicity syndrome, comparing the chimeric antigen receptor T-cell and teclistamab cohorts after propensity score matching. Provided in a separate Excel file.